323 related articles for article (PubMed ID: 14975461)
1. Outcome of acute ST-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: lessons from the GUSTO V trial.
Gurm HS; Lincoff AM; Lee D; Tang WH; Jia G; Booth JE; Califf RM; Ohman EM; Van de Werf F; Armstrong PW; Guetta V; Wilcox R; Topol EJ;
J Am Coll Cardiol; 2004 Feb; 43(4):542-8. PubMed ID: 14975461
[TBL] [Abstract][Full Text] [Related]
2. Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial.
Lincoff AM; Califf RM; Van de Werf F; Willerson JT; White HD; Armstrong PW; Guetta V; Gibler WB; Hochman JS; Bode C; Vahanian A; Steg PG; Ardissino D; Savonitto S; Bar F; Sadowski Z; Betriu A; Booth JE; Wolski K; Waller M; Topol EJ;
JAMA; 2002 Nov; 288(17):2130-5. PubMed ID: 12413372
[TBL] [Abstract][Full Text] [Related]
3. Outcome of acute myocardial infarction in patients with prior coronary artery bypass grafting treated with combination reduced fibrinolytic therapy and abciximab.
Mukherjee D; Gurm H; Tang WH; Roffi M; Wolski K; Moliterno DJ; Guetta V; Ardissinio D; Bode C; Steg G; Lincoff AM; Topol EJ
Am J Cardiol; 2002 Dec; 90(11):1198-203. PubMed ID: 12450598
[TBL] [Abstract][Full Text] [Related]
4. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial.
Topol EJ;
Lancet; 2001 Jun; 357(9272):1905-14. PubMed ID: 11425410
[TBL] [Abstract][Full Text] [Related]
5. ST-segment resolution 60 minutes after combination treatment of abciximab with reteplase or reteplase alone for acute myocardial infarction (30-day mortality results from the resolution of ST-segment after reperfusion therapy substudy).
Cura FA; Roffi M; Pasca N; Wolski KE; Lincoff AM; Topol EJ; Lauer MS;
Am J Cardiol; 2004 Oct; 94(7):859-63. PubMed ID: 15464665
[TBL] [Abstract][Full Text] [Related]
6. Benefical effects of reteplase in combination with abciximab: platelet/leukocyte interactions and coagulation system.
Szabo S; Walter T; Etzel D; Ehlers R; Kazmaier S; Beyer ME; Hoffmeister HM
Int J Clin Pharmacol Res; 2003; 23(2-3):37-40. PubMed ID: 15018016
[TBL] [Abstract][Full Text] [Related]
7. Early administration of reteplase plus abciximab vs abciximab alone in patients with acute myocardial infarction referred for percutaneous coronary intervention: a randomized controlled trial.
Kastrati A; Mehilli J; Schlotterbeck K; Dotzer F; Dirschinger J; Schmitt C; Nekolla SG; Seyfarth M; Martinoff S; Markwardt C; Clermont G; Gerbig HW; Leiss J; Schwaiger M; Schömig A;
JAMA; 2004 Feb; 291(8):947-54. PubMed ID: 14982910
[TBL] [Abstract][Full Text] [Related]
8. Combination pharmacotherapy with reduced-dose fibrinolytic and platelet GP IIb/IIIa inhibition.
Bush HS
J Emerg Med; 2003 Nov; 25(4):421-6. PubMed ID: 14654184
[TBL] [Abstract][Full Text] [Related]
9. Increased fibrin specificity and reduced paradoxical thrombin activation of the combined thrombolytic regimen with reteplase and abciximab versus standard reteplase thrombolysis.
Szabo S; Etzel D; Ehlers R; Walter T; Kazmaier S; Helber U; Beyer ME; Hoffmeister HM
Drugs Exp Clin Res; 2004; 30(2):47-54. PubMed ID: 15272642
[TBL] [Abstract][Full Text] [Related]
10. Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG Investigators.
Kleiman NS; Lincoff AM; Kereiakes DJ; Miller DP; Aguirre FV; Anderson KM; Weisman HF; Califf RM; Topol EJ
Circulation; 1998 May; 97(19):1912-20. PubMed ID: 9609084
[TBL] [Abstract][Full Text] [Related]
11. GUSTO V: combination drug treatment of acute myocardial infarction. Global Use of Strategies to Open Occluded Coronary Arteries.
Askari AT; Lincoff AM
Cleve Clin J Med; 2002 Jul; 69(7):554-60. PubMed ID: 12109639
[TBL] [Abstract][Full Text] [Related]
12. Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14. The Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators.
Antman EM; Gibson CM; de Lemos JA; Giugliano RP; McCabe CH; Coussement P; Menown I; Nienaber CA; Rehders TC; Frey MJ; Van der Wieken R; Andresen D; Scherer J; Anderson K; Van de Werf F; Braunwald E
Eur Heart J; 2000 Dec; 21(23):1944-53. PubMed ID: 11071800
[TBL] [Abstract][Full Text] [Related]
13. Combined Abciximab REteplase Stent Study in acute myocardial infarction (CARESS in AMI).
Di Mario C; Bolognese L; Maillard L; Dudek D; Gambarati G; Manari A; Guiducci V; Patrizi G; Rusconi LC; Piovaccari G; Hibon AR; Belpomme V; Indolfi C; Olivari Z; Steffenino G; Zmudka K; Airoldi F; Panzarasa R; Flather M; Steg PG
Am Heart J; 2004 Sep; 148(3):378-85. PubMed ID: 15389222
[TBL] [Abstract][Full Text] [Related]
14. Spotlight on abciximab in patients with ischemic heart disease undergoing percutaneous coronary revascularization.
Ibbotson T; McGavin JK; Goa KL
Am J Cardiovasc Drugs; 2003; 3(5):381-6. PubMed ID: 14728074
[TBL] [Abstract][Full Text] [Related]
15. Effect of abciximab on prothrombin activation and thrombin generation in patients with acute myocardial infarction also receiving reteplase.
Merlini PA; Repetto A; Andreoli AM; Ricci S; Lombardi A; Finardi A; Dipasquale G; Lamponi M; Mannucci PM; Ardissino D
Am J Cardiol; 2004 Jan; 93(2):195-8. PubMed ID: 14715345
[TBL] [Abstract][Full Text] [Related]
16. Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: design and rationale of the Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events (FINESSE) trial.
Ellis SG; Armstrong P; Betriu A; Brodie B; Herrmann H; Montalescot G; Neumann FJ; Smith JJ; Topol E;
Am Heart J; 2004 Apr; 147(4):E16. PubMed ID: 15077099
[TBL] [Abstract][Full Text] [Related]
17. [Combination therapy for acute myocardial infarction with glycoprotein IIb/IIIa inhibitors and fibrinolysis].
Ottani F; Bresciani B; La Vecchia L; Favero L; Fontanelli A; Galvani M
Ital Heart J Suppl; 2002 May; 3(5):544-54. PubMed ID: 12064194
[TBL] [Abstract][Full Text] [Related]
18. Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. Stent versus Thrombolysis for Occluded Coronary Arteries in Patients with Acute Myocardial Infarction Study Investigators.
Schömig A; Kastrati A; Dirschinger J; Mehilli J; Schricke U; Pache J; Martinoff S; Neumann FJ; Schwaiger M
N Engl J Med; 2000 Aug; 343(6):385-91. PubMed ID: 10933737
[TBL] [Abstract][Full Text] [Related]
19. Flow cytometric monitoring of glycoprotein IIb/IIIa blockade and platelet function in patients with acute myocardial infarction receiving reteplase, abciximab, and ticlopidine: continuous platelet inhibition by the combination of abciximab and ticlopidine.
Peter K; Kohler B; Straub A; Ruef J; Moser M; Nordt T; Olschewski M; Ohman ME; Kübler W; Bode C
Circulation; 2000 Sep; 102(13):1490-6. PubMed ID: 11004138
[TBL] [Abstract][Full Text] [Related]
20. Reteplase monotherapy and reteplase/abciximab combination therapy in peripheral arterial occlusive disease: results from the RELAX trial.
Ouriel K; Castaneda F; McNamara T; Swischuk J; Tepe G; Smith JJ; Clark J; Duda S
J Vasc Interv Radiol; 2004 Mar; 15(3):229-38. PubMed ID: 15028807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
